Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors.
Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany. guenter.krause@uk-koeln.de.|Cologne Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD Cologne), Cologne, Germany. guenter.krause@uk-koeln.de.
Günter
G
Krause
Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.
Imaan
I
Baki
Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.|Cologne Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD Cologne), Cologne, Germany.
Susan
S
Kerwien
Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.|Cologne Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD Cologne), Cologne, Germany.
Eva
E
Knödgen
Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.|Cologne Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD Cologne), Cologne, Germany.
Lars
L
Neumann
Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.|Cologne Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD Cologne), Cologne, Germany.
Elisa
E
Göckeritz
Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.
Thomas
T
Landwehr
Boehringer Ingelheim RCV GmbH & Co KG, Wien, Austria.
Karl-Heinz
KH
Heider
Department I of Internal Medicine, Centre of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany.|Cologne Cluster of Excellence on Cellular Stress Responses in Aging-associated Diseases (CECAD Cologne), Cologne, Germany.
Michael
M
Hallek
D000906:Antibodies / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002470:Cell Survival / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D059470:Tetraspanins / Q000276:immunology; D014407:Tumor Cells, Cultured
D000906:Antibodies; D000951:Antigens, Neoplasm; C059071:CD37 protein, human; D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D059470:Tetraspanins
CD37; chronic lymphocytic leukaemia; direct cell death; drug combinations; monoclonal antibodies